The US Food and Drug Administration (FDA) has approved a new diabetes drug for the treatment of type 2 diabetes . The diabetes drug has been in clinical trials for some time, and some US physicians are understood to be relieved to now be able to prescribe the medication .
The drug, Victoza, has been brought to market by Novo Nordisk . Victoza stimulate the pancreas to provide more insulin to patients with diabetes, but only when glucose levels are high. This means that insulin injections do not take blood sugar as low as with some other drugs.
Victoza has also caused a stir because it can lead to weight loss by suppressing the appetite. Victoza is taken once daily, as opposed to Byetta which is taken twice a day. It is expected that Victoza will be prescribed within the next two weeks. However, Victoza is expensive, and many specialists believe that the drug will mostly be used in combination with other diabetes drugs .
Type 2 diabetes drug gets Food and Drug Administration approval
Thu, 28 Jan 2010
Recommended links
Diabetes communityDiabetes myLifestyle
Type 2 diabetes
Diabetes and byetta
Diabetes pensions and annuities
Diabetes.co.uk ID alert wristband
The Diet Plate to help control diabetes
Lexicon diabetes drug hits mid-stage trial
Diabetes drug clinical trials underway
Death risk increased 60 per cent by diabetes drug
Roche diabetes drug hits targets
New type 1 diabetes drug
Diabetes drug warning has doctors on alert
Label change for type 2 diabetes drug
Diabetes prevention using diet, not drugs
Diabetes drug better for weight loss
Diabetes drug may have pancreatitis risk
Denial over diabetes drug link
Heart risk not alleviated by diabetes drugs
Obesity increases diabetes drug bill
Med diet could delay diabetes drugs
Diabetes drug prescriptions must stop, study says
Stop prescribing diabetes drug, scientists say
New diabetes drug same price
Dementia drug risk amongst people with diabetes
Iron binding drug could help diabetes neuropathy
Diabetes drug cleared of cancer risk
Canada reviews diabetes drug
Diabetes drug review causes share climb
Sanofi maintain diabetes drug no riskier than insulin
Diabetes drug cleared for European market
Drug association encourages use of diabetes drug





Join us